UK regulator suspends Amgen's Tavneos for new patients over unreliable data

Britain’s medicines regulator suspended Tavneos (Amgen) for new patients, citing that the key study supporting approval was unreliable. The move is a significant regulatory setback for Amgen’s rare-disease franchise and increases near-term commercial uncertainty. Impact is likely to pressure sentiment around the drug’s timeline to remediation and potential reinstatement.